Vis børsmeldingen
Highlights review
fimaNAc - bioprocessing
The bioprocessing program for use of fimaNAc in gene therapy manufacturing has
generated new results that add to the initial patent application filed in
2H 2022. Continued focus on generating results that can trigger field testing
with potential customers to get feedback and develop a competitive technology.
fimaNAc - dermatology
For dermatology the study to demonstrate topical fimaNAc-mediated nucleic acid
delivery in a preclinical wound model is completed. The study demonstrated
significant delivery in a simplified model, but these results were not
translatable into the selected full-scale model when testing topical delivery of
unprotected (“naked”) nucleic acid, which is a challenging approach.
PCI Biotech will evaluate these initial results for the project and assess the
collaborative landscape for fimaNAc in dermatology.
fimaVacc - intratumoural immunotherapy
For fimaVacc we are exploring approaches aimed at identifying novel
immunotherapy treatment combinations, and a patent application for an
undisclosed treatment approach was filed in 1H 2023.
Corporate
The cash position of NOK 45 million enables a financial runway towards the end
of 2024 with current plans.
Ronny Skuggedal, CEO of PCI Biotech, comments: “We have seen promising early
signs of enhanced delivery of nucleic acids for dermatology in simplified
preclinical settings, but we were unfortunately not able to translate these
promising results at our first attempt in a relevant and challenging skin model.
The bioprocessing program has made good progress since the first patent
application was filed in 2H 2022. We continue to pursue external feedback, by
seeking field testing in collaboration with potential future customers.”
PCI Biotech will focus resources on research and development. Hence, moving
forward, PCI Biotech will report financial results on a half yearly basis, per
June 30 and December 31. We will continue to update our shareholders on a
regular basis, including updates on financial information. An updated financial
calendar will be announced shortly.
A live webcast in Norwegian will be held today, 31 August 2023, at 08:30am -
09:30am CEST (local time).
The presentation can be followed as a live webcast, accessed through the link
https://channel.royalcast.com/hegnarmedia/#!/hegnarmedia/20230831_1 or the
company’s website under “Investors - Reports and presentations - Webcasts”.
There will be a Q&A session at the end of the presentation and it will be
possible to post written questions through the webcast console.
The interim report and the presentation will also be available on www.newsweb.no
and on the company’s webpage, www.pcibiotech.com from 07:00am (CEST) today.
For further information, please contact:
Ronny Skuggedal, CEO / CFO
Email: rs@pcibiotech.no
Mobile: +47 9400 5757
About PCI Biotech
PCI Biotech is a biopharmaceutical company focussing on development and
commercialisation of novel therapies and new technologies through its innovative
photochemical internalisation (PCI) technology platform. PCI induces triggered
endosomal release that is used to unlock the true potential of therapeutic
modalities.
The fimaNAc programme utilises the proven capability of the PCI technology for
intracellular delivery of nucleic acids. The technology can be used for most
types of nucleic acids, ranging from oligonucleotides through mRNA and plasmids
to viral vectors. The development of the fimaNAc programme is currently focussed
on selected applications within dermatology and bioprocessing, well suited to
the specific strengths of the PCI technology. The fimaVacc programme aims to
enhance immunotherapy in cancer, by triggered endosomal release of antigens or
nucleic acids encoding antigens, or immunostimulatory factors. For further
information, please visit: www.pcibiotech.co
Contact information: PCI Biotech Holding ASA, Ullernchausséen 64, N-0379
Oslo
Forward-looking statements
This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.
PCI Biotech disclaims any obligation to update or revise any forward-looking
statements, whether as a result of new information, future events or otherwise.
Kilde
